Can proton pump inhibitors cause QT‑interval prolongation?

Yes, Proton Pump Inhibitors Can Cause QT Prolongation

Proton pump inhibitors (PPIs) are definitively associated with QT interval prolongation and should be recognized as a cardiac risk, particularly in critically ill patients and those with heart failure. 1, 2

Evidence Strength and Clinical Significance

The most recent and highest-quality evidence demonstrates that PPIs are the most common cause of non-cardiac drug-induced QTc interval prolongation in hospitalized patients, with esomeprazole representing 46.5% of cases 1. In critically ill ICU patients, PPI use independently increases the risk of QT prolongation with an odds ratio of 1.66 compared to H2-receptor antagonists and 1.54 compared to no acid suppression therapy 2.

Key Clinical Findings:

• Real-world prevalence: Among hospitalized patients on QTc-prolonging medications, 75.5% demonstrated prolonged QTc values, with PPIs being the leading causative agent 1

• ICU-specific risk: The incidence of QT prolongation in ICU patients on PPIs was 8.5%, compared to only 3.3% with H2-blockers 2

• Individual PPI differences: Pantoprazole (OR 2.14) and lansoprazole (OR 1.80) carry higher risk than omeprazole 2

• Cardiac arrest association: Current PPI use is associated with increased out-of-hospital cardiac arrest risk (OR 1.32), with this risk persisting even in patients without cardiovascular comorbidities (OR 1.84) 3

High-Risk Populations Requiring Vigilance

Heart failure patients face the highest risk, with an odds ratio of 4.98 for QTc prolongation when exposed to PPIs 1. The geriatric population is particularly vulnerable, with QTc prolongation affecting 27.3% on admission and increasing to 42.2% after 7 days of hospitalization 4.

Risk Stratification:

• Baseline QTc ≥500 ms: Withhold PPIs 5
• Heart failure patients: Avoid PPIs or use alternative therapy
• Critically ill patients: Monitor QTc and discontinue if exceeds 500 ms 5
• Polypharmacy with other QT-prolonging drugs: Avoid combination 2

Mechanism and Clinical Context

While the 2010 AHA/ACC guideline 6 does not specifically list PPIs among high-risk drugs like antiarrhythmics (1-10% TdP incidence), the emerging evidence from 2024-2025 demonstrates that PPIs impair cardiac repolarization through ion channel effects 3. The risk appears dose-dependent and concentration-related for most QT-prolonging drugs, though absolute TdP incidence with PPIs remains lower than traditional antiarrhythmics.

Practical Management Algorithm

1. Before initiating PPI therapy:

   • Obtain baseline ECG in high-risk patients (heart failure, elderly, ICU patients)
   • Check electrolytes (potassium, magnesium, calcium)
   • Review medication list for other QT-prolonging agents

2. During PPI therapy:

   • Monitor QTc if baseline >450 ms or risk factors present
   • Discontinue if QTc exceeds 500 ms 5
   • Prefer omeprazole over pantoprazole or lansoprazole in high-risk patients 2

3. Alternative strategies:

   • Consider H2-receptor antagonists (no significant QT risk difference vs. no acid suppression) 2
   • Reassess ongoing need for PPI therapy regularly
   • Note that past PPI use shows no residual risk (OR 1.01) 3

Critical Caveats

The pediatric data is reassuring: A 2023 study found no significant QTc prolongation in children after 1 month of PPI treatment 7, suggesting age-dependent susceptibility.

Drug interactions matter: Several medications show synergistic QT prolongation risk when combined with PPIs 2, making polypharmacy review essential.

Electrolyte monitoring is mandatory: PPIs can cause hypocalcemia 8, which independently prolongs QTc and increases arrhythmia risk. Hypokalemia and hypomagnesemia further compound this risk 5.

The widespread use of PPIs—often without clear indication—combined with their documented cardiac risks necessitates heightened clinical awareness and routine ECG monitoring in vulnerable populations 4, 3.